ライフサイエンスコーパス: standard chemotherapy

1 also exhibit strong synergistic effects with standard chemotherapy.

2 t would be associated with a better QoL than standard chemotherapy.

3 all survival with capecitabine compared with standard chemotherapy.

4 ated in younger adults in the frontline with standard chemotherapy.

5 nd greatly augments the antitumor effects of standard chemotherapy.

6 n in patients with sarcomas after failure of standard chemotherapy.

7 cer treatment, when used in conjunction with standard chemotherapy.

8 onse rate in colorectal cancer refractory to standard chemotherapy.

9 and compare autologous transplantation with standard chemotherapy.

10 he risk to the fetus might not reach that of standard chemotherapy.

11 , in combinations together and combined with standard chemotherapy.

12 s and seemingly higher overall survival than standard chemotherapy.

13 emotherapy-naive NSCLC patients treated with standard chemotherapy.

14 ed response rates and survival compared with standard chemotherapy.

15 he first 30 days of treatment in addition to standard chemotherapy.

16 ve and to express p53, adverse features with standard chemotherapy.

17 ure rate and therefore, since 1984, has been standard chemotherapy.

18 Multiple myeloma is incurable with standard chemotherapy.

19 ewly diagnosed tumors for which there was no standard chemotherapy.

20 prove therapeutic responses as compared with standard chemotherapy.

21 mine its activity in patients who had failed standard chemotherapy.

22 ntal cancer, particularly when combined with standard chemotherapy.

23 anted, including its use in conjunction with standard chemotherapy.

24 rognostic marker for response of patients to standard chemotherapy.

25 t there is cross-resistance between 9-AC and standard chemotherapy.

26 recurrence in OC and enhance the efficacy of standard chemotherapy.

27 stic leukemia (ALL) and confer resistance to standard chemotherapy.

28 drug dose administered to brain tumors than standard chemotherapy.

29 r experimental anticancer therapy along with standard chemotherapy.

30 a 17p deletion, which predicts resistance to standard chemotherapy.

31 medical conditions are less able to undergo standard chemotherapy.

32 is a need for more effective treatment than standard chemotherapy.

33 ties and chemoresistance are shortcomings of standard chemotherapy.

34 eukemia (AML) have a high relapse rate after standard chemotherapy.

35 nation therapies with myeloid inhibitors and standard chemotherapy.

36 ow PD-L1 expression, clinicians should offer standard chemotherapy.

37 heckpoint inhibitor, clinicians should offer standard chemotherapy.

38 fective therapies against cells resistant to standard chemotherapy.

39 older AML patients with del(5q) who declined standard chemotherapy.

40 sensitize nonresponsive NSCLC cell lines to standard chemotherapy.

41 lays tumor growth and enhances the effect of standard chemotherapies.

42 lineage leukemia-driven AML, and outperforms standard chemotherapies.

43 and variable response of advanced tumors to standard chemotherapies.

44 d in this phase 2 study (n = 171) to receive standard chemotherapy (3 + 7) with or without bevacizuma

45 After standard chemotherapy, 41 patients with non-Hodgkin's B-

46 < 0.01, t test), which performed better than standard chemotherapy (5-FU and oxaliplatin).

47 ficacy of an alternate regimen that combines standard chemotherapy, a proteasome inhibitor, and high-

48 The addition of ifosfamide to standard chemotherapy achieved a 3-year EFS rate of 61%.

49 The addition of MTP to standard chemotherapy achieved a 3-year EFS rate of 68%.

50 ia stem cells (LSCs), which are resistant to standard chemotherapy agents and likely to be a major ca

51 Systemic treatments for lung cancer with standard chemotherapy agents are still relatively ineffe

52 esyl transferase inhibitor combinations with standard chemotherapy agents, future studies of this age

53 ompared with sensitivities to a panel of 122 standard chemotherapy agents, the most striking relation

54 e myeloid leukemia (AML) in combination with standard chemotherapy agents, the pediatric maximum-tole

55 y for synergistic sensitization of NSCLCs to standard chemotherapy agents, which seems to occur indep

56 tumors are less likely to benefit from these standard chemotherapy agents.

57 wth as well as make tumors more sensitive to standard chemotherapy agents.

58 We randomly assigned 234 patients to receive standard chemotherapy alone and 235 patients to receive

59 enefit in survival, TTP, or RR compared with standard chemotherapy alone.

60 stress responses to enhance the efficacy of standard chemotherapies and evolving cancer immunotherap

61 (38%) of 135 parents overall would recommend standard chemotherapy and 46 (33%) of 140 would recommen

62 -year-old patient with myeloma refractory to standard chemotherapy and autologous transplantation rec

63 ents with T790M-positive resistance, whereas standard chemotherapy and clinical trials are preferred

64 icult disease to treat, being incurable with standard chemotherapy and having a median survival of ap

65 HCC is not amenable to standard chemotherapy and is resistant to radiotherapy.

66 Although data are limited, standard chemotherapy and radiation therapy have not bee

67 ic cancer, which is notoriously resistant to standard chemotherapy and radiation.

68 The addition of cetuximab to standard chemotherapy and radiotherapy cannot be recomme

69 also possess resistant phenotypes that evade standard chemotherapy and radiotherapy, resulting in tum

70 ntain hypoxic regions which are resistant to standard chemotherapy and radiotherapy.

71 e a common cause of resistance of cancers to standard chemotherapy and, thus, treatment failure.

72 ad shown progressive disease while receiving standard chemotherapy, and 55 patients (23%) had chromos

73 reatment compare favorably with results with standard chemotherapy, and IDEC-C2B8 has a better safety

74 atment most widely used, to date there is no standard chemotherapy, and new combinations with targete

75 iridol, other schedules and combination with standard chemotherapies are ongoing.

76 tion with rituximab (chimeric anti-CD20) and standard chemotherapy are ongoing.

77 n of these targeted epigenetic agents to the standard chemotherapy backbone is a promising approach t

78 arsenic trioxide treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin

79 nd are associated with lower cure rates from standard chemotherapy-based treatment.

80 yeloma can prolong survival as compared with standard chemotherapy but cannot be considered curative,

81 Improving the efficacy of standard chemotherapy by targeting DNA repair mechanisms

82 Preoperative standard chemotherapy can be recommended for downsizing

83 Resistance to standard chemotherapy (carboplatin + paclitaxel) is one

84 s for this class of patients is poor, and no standard chemotherapy combination so far has demonstrate

85 ludarabine and high-dose cytosine (FLA) with standard chemotherapy comprising cytosine arabinoside, d

86 Standard chemotherapy consisting of doxorubicin-cyclopho

87 Infants received standard chemotherapy, depending on MYCN status and ploi

88 ition of ifosfamide in this dose schedule to standard chemotherapy did not enhance EFS.

89 udy show that the addition of bevacizumab to standard chemotherapy does not improve the therapeutic o

90 Notably, in comparison to the standard chemotherapy drug cytosine arabinoside (Ara-C),

91 ombination of RGD-M/sPMI and temozolomide--a standard chemotherapy drug for GBM increased antitumor e

92 s and subsequently enhanced sensitivity to a standard chemotherapy drug, cyclophosphamide, in DLBCL c

93 oside (ara-C) and gemcitabine (dFdC) are two standard chemotherapy drugs used in the treatment of pat

94 stage I, II, IIIA, or IIIB breast cancer to standard chemotherapy (either cyclophosphamide, methotre

95 Standard chemotherapy fails in 40% to 50% of patients wi

96 TERPRETATION: The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy u

97 ed in combination with radioimmunotherapy or standard chemotherapy for a more durable response.

98 Standard chemotherapy for advanced ovarian cancer curren

99 ved the use of rituximab in combination with standard chemotherapy for aggressive NHL.

100 of patients who have experienced failure of standard chemotherapy for AIDS-KS.

101 r colon cancer (92.7% vs. 90.5%; P < 0.010), standard chemotherapy for diffuse large B-cell non-Hodgk

102 The most standard chemotherapy for metastatic disease is gemcitab

103 Patients treated with standard chemotherapy for metastatic or relapsed cervica

104 Standard chemotherapy for newly diagnosed ovarian cancer

105 Platinum-based regimens are the standard chemotherapy for patients with advanced non-sma

106 Docetaxel is a standard chemotherapy for patients with metastatic prost

107 d safety of adding bevacizumab to first-line standard chemotherapy for treatment of extensive-stage s

108 Even parents who would not recommend standard chemotherapy generally felt the physician shoul

109 d irinotecan are being tested to replace the standard chemotherapy given during thoracic radiation.

110 rognosis disease, 332 (66%) died (174 in the standard chemotherapy group and 158 in the bevacizumab g

111 At baseline, 684 (90%) of women in the standard chemotherapy group and 691 (90%) of those in th

112 764 women were randomly assigned to the standard chemotherapy group and 764 to the bevacizumab g

113 bevacizumab group and 388 (51%) women in the standard chemotherapy group provided QoL data.

114 obal QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab grou

115 l time 44.6 months [95% CI 43.2-45.9] in the standard chemotherapy group vs 45.5 months [44.2-46.7] i

116 oups (49.7 months [95% CI 48.3-51.1]) in the standard chemotherapy group vs 48.4 months [47.0-49.9] i

117 in the capecitabine group versus 85% in the standard-chemotherapy group, and the overall survival ra

118 pecitabine, twice as many patients receiving standard chemotherapy had moderate-to-severe toxic effec

119 Addition of anti-VEGF antibody therapy to standard chemotherapies has improved survival and is an

120 Standard chemotherapy has a response rate of around 25%

121 se of epithelial ovarian tumors treated with standard chemotherapy has highlighted the necessity to i

122 e addition of thoracic radiotherapy (TRT) to standard chemotherapy has led to improvements in long-te

123 cell lung cancer (NSCLC) patients receiving standard chemotherapy (hazard ratio=0.63, P=0.07).

124 w likelihood of durable complete response to standard chemotherapy, ie, weight loss, visceral metasta

125 nt therapy in conjunction with radiotherapy, standard chemotherapy, immunotherapy, or surgical debulk

126 ective was to determine whether adding GO to standard chemotherapy improved event-free survival (EFS)

127 agents, namely bevacizumab and cetuximab, to standard chemotherapies in stage III disease, despite im

128 evaluated the activity of verapamil added to standard chemotherapy in both C3HeB/FeJ (which produce n

129 FR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advance

130 indings indicate that FLA may be inferior to standard chemotherapy in high-risk AML and that the outc

131 stent senescent cells that accumulate during standard chemotherapy in NSCLC and HNSCC.

132 of sequential gemtuzumab ozogamicin (GO) and standard chemotherapy in older patients with newly diagn

133 and BAY 12-9566 alone or in combination with standard chemotherapy in patients with advanced cancers

134 The addition of bevacizumab to standard chemotherapy in patients with advanced ovarian

135 rgeted therapy by combining trastuzumab with standard chemotherapy in patients with metastatic osteos

136 icity of this combination when provided with standard chemotherapy in patients with newly diagnosed m

137 Crizotinib is superior to standard chemotherapy in patients with previously treate

138 sess the benefit of addition of cetuximab to standard chemotherapy in patients with resectable colore

139 ed as window therapy and in combination with standard chemotherapy in pediatric patients with newly d

140 Pamidronate is a useful adjunct to standard chemotherapy in the palliative treatment of met

141 ree survival and response rate compared with standard chemotherapy in this setting; however, resistan

142 growth kinetics and drug sensitivity against standard chemotherapy in vivo.

143 inferiority of capecitabine as compared with standard chemotherapy in women with breast cancer who we

144 do not respond to or relapse soon after the standard chemotherapy, indicating a critical need to bet

145 monstrated that the addition of rituximab to standard chemotherapy induction has improved the overall

146 All patients received standard chemotherapy induction regimens.

147 Patients were randomly assigned to receive standard chemotherapy (induction therapy with daunorubic

148 apse, metastasis, and drug resistance render standard chemotherapy ineffective in the treatment of TN

149 ether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in pat

150 Standard chemotherapy is poorly tolerated in patients wh

151 , C-reactive protein </= 4 mg/L, and pre-HDT standard chemotherapy </= 12 months.

152 Notably, the timing of administration of standard chemotherapy markedly impacted the induction of

153 lication of 2-FG as an adjuvant treatment to standard chemotherapy may enhance the treatment of retin

154 therapy was highly likely to be inferior to standard chemotherapy met a prescribed level, and enroll

155 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevac

156 Beyond standard chemotherapy, newer treatment regimens in HNSCC

157 would improve patient outcome compared with standard chemotherapy of similar duration.

158 d its efficacy in NHL patients refractory to standard chemotherapy or immunotherapy with the widely u

159 ie as patients who were randomly assigned to standard chemotherapy (P=0.02).

160 Compared with patients who were treated with standard chemotherapy, patients who were treated with ca

161 garding how to optimally integrate them with standard chemotherapy platforms.

162 emotherapy alone and 235 patients to receive standard chemotherapy plus trastuzumab.

163 n implicated in tumor growth, sensitivity to standard chemotherapy, prognosis of patients, and diseas

164 trial, the sequential combination of GO and standard chemotherapy provides no benefit for older pati

165 For most patients, however, standard chemotherapy, radiation therapy, topical therap

166 f chemotherapy flow sheets; and adherence to standard chemotherapy recommendations for patients with

167 Patients with breast cancer treated with a standard chemotherapy regimen (n = 764) were enrolled in

168 ial comparing paclitaxel plus cisplatin to a standard chemotherapy regimen consisting of cisplatin an

169 ) expression renders cells more sensitive to standard chemotherapy regimen due to a DNA repair defect

170 ine, doxorubicin, and cisplatin (M-VAC), the standard chemotherapy regimen for locally advanced and m

171 There is currently no standard chemotherapy regimen for patients with lymphoid

172 There is no standard chemotherapy regimen for relapsed disease, alth

173 ls confirm that the addition of rituximab to standard chemotherapy regimens (chemoimmunotherapy) impr

174 ues to support the addition of ifosfamide to standard chemotherapy regimens and help further refine p

175 Both standard chemotherapy regimens and mAbs directed against

176 Current research suggests that standard chemotherapy regimens have been optimized to ma

177 rently, there is little information on using standard chemotherapy regimens in AML xenografts.

178 accrued by the same patient while receiving standard chemotherapy regimens just before (PRE; n = 41)

179 One possibility is that standard chemotherapy regimens that include CYP3A substr

180 cacy and safety of bevacizumab combined with standard chemotherapy regimens versus chemotherapy alone

181 bevacizumab (BV) when combined with several standard chemotherapy regimens versus those regimens alo

182 ents with gynecologic malignancies beginning standard chemotherapy regimens were enrolled between Apr

183 In combination with standard chemotherapy regimens, bevacizumab significantl

184 elated to the toxicity and deliverability of standard chemotherapy regimens.

185 ntravenous (IV) rhuMAbVEGF with one of three standard chemotherapy regimens.

186 f patients achieve long-term remissions with standard chemotherapy regimens.

187 pecificity and, thus, improved efficacy over standard chemotherapy regimens.

188 Although standard chemotherapy remains associated with a poor out

189 HL, FDG-PET performed after a few cycles of standard chemotherapy seems to be a reliable prognostic

190 ultitargeted kinase inhibitor midostaurin to standard chemotherapy significantly prolonged overall an

191 lled and randomly assigned in a 1:1 ratio to standard chemotherapy (six 3-weekly cycles of intravenou

192 Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel

193 When combined with standard chemotherapies, some significant improvements i

194 oma, the feasibility of combining HAART with standard chemotherapy, the molecular classification of l

195 However, with the addition of rituximab to standard chemotherapy, the prognostic significance of th

196 ncer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of

197 0.46; P = .02) were less likely to recommend standard chemotherapy to other families.

198 how that inhibition of SMYD2 cooperates with standard chemotherapy to treat PDAC cells and tumors.

199 had received 12 months or less of preceding standard chemotherapy, to evaluate the feasibility of la

200 andomisation to receive either six cycles of standard chemotherapy (total 18 weeks) with carboplatin

201 9907 was a randomly assigned trial comparing standard chemotherapy versus oral chemotherapy with cape

202 val time 34.5 months [95% CI 32.0-37.0] with standard chemotherapy vs 39.3 months [37.0-41.7] with be

203 Standard chemotherapy was superior to capecitabine in im

204 operable mCRC and prior stable disease after standard chemotherapy were enrolled at a single center a

205 ginal haemorrhage, in a patient treated with standard chemotherapy) were reported.

206 reased response rate and poorer prognosis to standard chemotherapy when compared with lymphoma in the

207 , including the SQUIRE trial, which compared standard chemotherapy with and without necitumumab as fi

208 ere randomly assigned to receive 49 weeks of standard chemotherapy with doxorubicin, vincristine, cyc

209 Whether crizotinib is superior to standard chemotherapy with respect to efficacy is unknow

210 e-receptor-negative breast cancer to receive standard chemotherapy with the GnRH agonist goserelin (g

211 rates of pathological complete response than standard chemotherapy with trastuzumab among patients wi

212 n cancer with the addition of bevacizumab to standard chemotherapy, with the greatest effect in patie

213 GnRH agonist goserelin (goserelin group) or standard chemotherapy without goserelin (chemotherapy-al

214 active in patients with a FLT3 mutation - to standard chemotherapy would prolong overall survival in